| Trial | control | p<0.05 | harm | NS |
|---|
| vs placebo (on top statin) | | | |
| CLAS, 1987 | vs placebo (on top statin) | | | all cause deaths 0.00 [0.00; NaN] coronary deaths 0.00 [0.00; NaN] non cardiovascular death NaN [NaN; NaN] |
| Carlson (Stockholm), 1977 | vs placebo (on top statin) | all cause deaths 0.74 [0.55; 0.98] coronary deaths 0.64 [0.46; 0.88] coronary events 0.71 [0.55; 0.92] | | décès par cancer 0.66 [0.19; 2.31] MI non fatal 0.69 [0.46; 1.03] |
| CDP niacin, 1975 | vs placebo (on top statin) | coronary events 0.85 [0.76; 0.96] MI non fatal 0.74 [0.60; 0.90] | | all cause deaths 0.96 [0.85; 1.08] coronary deaths 0.95 [0.82; 1.09] décès par cancer 0.93 [0.44; 2.00] non cardiovascular death 1.15 [0.77; 1.70] |
| VA drugs, 1968 | vs placebo (on top statin) | | | all cause deaths 1.03 [0.59; 1.82] cardiac death 1.05 [0.56; 1.95] non cardiovascular death 0.93 [0.17; 4.96] |
| AIM-HIGH, 2011 | vs placebo (on top statin) | | | major CHD events 1.04 [0.80; 1.34] stroke 1.78 [0.95; 3.33] cardiovascular events 1.02 [0.87; 1.18] |
| HPS 2-Thrive | vs placebo (on top statin) | | | coronary death 1.04 [0.88; 1.22] all-cause death 1.09 [0.99; 1.20] major CHD events 0.96 [0.87; 1.07] cardiovascular deaths 1.09 [0.96; 1.24] stroke 1.00 [0.88; 1.13] cardiovascular events 0.96 [0.90; 1.03] |
| Oxford Niaspan Study, 2009 | vs placebo (on top statin) | | | |
| ARBITER 2, 2009 | vs placebo (on top statin) | | | major CHD events 0.92 [0.13; 6.38] cardiovascular deaths 0.46 [0.04; 4.97] stroke 0.00 [0.00; NaN] cardiovascular events 0.39 [0.11; 1.47] |
| HATS, 2001 | vs placebo (on top statin) | | | all-cause death 1.00 [0.06; 15.71] major CHD events 0.20 [0.02; 1.63] cardiovascular deaths 1.00 [0.06; 15.71] stroke 0.00 [0.00; NaN] cardiovascular events 0.40 [0.13; 1.22] |
| ARBITER 6-HALTS (niacin vs ezetimibe), 2009 | vs placebo (on top statin) | major CHD events 0.21 [0.05; 0.95] | cardiovascular events 29.49 [15.69; 55.42] | |
| Guyton, 2008 | vs placebo (on top statin) | | cardiovascular events 22.53 [5.61; 90.57] | major CHD events 0.40 [0.03; 6.41] stroke 0.00 [0.00; NaN] |
| UCSF SCOR, 1990 | vs placebo (on top statin) | | | major CHD events 0.00 [0.00; NaN] cardiovascular events 0.00 [0.00; NaN] |
| FATS, 1990 | vs placebo (on top statin) | cardiovascular events 0.22 [0.05; 0.94] | | |
| Trial | Treatments | Patients | Method |
|---|
| CLAS, 1987 | Colestipol + Niacin 30 g / j 3-12 g / j (titré sur chaque patient sur la base de la baisse de cholestérol sanguin) (n=94) vs. placebo: methyl cellulose (n=94) | Patients coronariens avec antécédent de revascularisation chirurgicale coronarienne. | Non déterminable Parallel groups Sample size: 94/94 Primary endpoint: Changement de score coronarien global FU duration: 2 ans La randomisation est basée sur des blocs de groupes d'age et sur l'hôpital où l'angiogramme a été réalisé.
L'évaluation des différents critères de jugement est faite en aveugle. |
| CLAS, 1987 | colestipol + niacin (n=-9) vs. placebo (n=94) | nonsmoking men aged 40 to 59 years with previous coronary bypass surgery | double blind Parallel groups Sample size: -9/94 Primary endpoint: angiography FU duration: 2 years |
| Carlson (Stockholm), 1977 | clofibrate, 1 g twice daily, and nicotinic acid 1 g three times daily (n=279) vs. control (n=276)
| survivors of a myocardial infarction below 70 years of age
| open Parallel groups Sample size: 279/276 Primary endpoint: ND FU duration: 5 years
|
| CDP niacin, 1975 | niacin 3 mg/d (n=1119) vs. placebo (n=2789)
| Hommes, de 30 à 64 ans
| double blind Parallel groups Sample size: 1119/2789 Primary endpoint: Mortalité totale FU duration: 6.2 years
|
| VA drugs, 1968 | niacin (n=77) vs. (n=143) | | double blind Parallel groups Sample size: 77/143 Primary endpoint: FU duration: 3.2 years |
| AIM-HIGH, 2011 | high-dose, extended-release niacin in gradually increasing doses up to 2000 mg daily (+ simvastatin) (n=1718) vs. placebo (n=1691) | patients with a history of cardiovascular disease, high triglycerides, and low levels of HDL cholesterol | double blind Parallel groups Sample size: 1718/1691 Primary endpoint: CHD death, MI, ischaemic stroke, NSTEMI FU duration: 32 months |
| HPS 2-Thrive | 2 g of extended-release niacin and 40 mg of laropiprant (n=12838) vs. placebo (n=12835) | patients with vascular disease | double blind Parallel groups Sample size: 12838/12835 Primary endpoint: CHD death, stoke, CABG FU duration: 3.9y (median) |
| Oxford Niaspan Study, 2009 | niacin 2g daily (added to statin therapy) (n=35) vs. placebo (statins alone) (n=36) | patients with low HDL-C (<40 mg/dl) and either a type 2 diabetes with coronary heart disease or a carotid/peripheral atherosclerosis | double blind Parallel groups Sample size: 35/36 Primary endpoint: carotid artery wall area FU duration: 1 year |
| ARBITER 2, 2009 | long-acting niacin target dose of 1 g/day (added to statin therapy) (n=87) vs. placebo (n=80) | patients with known coronary artery disease and well controlled on statin therapy | double blind Parallel groups Sample size: 87/80 Primary endpoint: carotid intima-media thickness FU duration: 1 y |
| HATS, 2001 | simvastatin plus niacin (n=73) vs. placebo (n=73) factorial design with antioxidant vitamins | patients with coronary disease, low HDL cholesterol levels and normal LDL cholesterol levels | double blind Factorial plan Sample size: 73/73 Primary endpoint: cardiovascular event FU duration: 3 y |
| ARBITER 6-HALTS (niacin vs ezetimibe), 2009 | extended-release niacin 1 g/d, titrated to max tolerable dose up to 2 g/d (HDL-focused strategy) (n=97) vs. ezetimibe 10 mg/d (LDL-focused strategy) (n=111) | patients with known coronary or vascular disease or coronary risk equivalents | open Parallel groups Sample size: 97/111 Primary endpoint: carotid intima-media thickness FU duration: 14 months |
| Guyton, 2008 | Niacin 2 g ezetimibe 10 mg simvastatin 20 mg (n=-9) vs. Ezetimibe 10 mg simvastatin 20 mg (n=-9) | patients with type IIa or IIb hyperlipidemia | double-blind Parallel groups Sample size: -9/-9 Primary endpoint: FU duration: 24 weeks |
| UCSF SCOR, 1990 | Niacin 0–7.5 g colestipol 15–20 g (n=72) vs. Conventional therapy (n=0) | patients with heterozygous familial hypercholesterolemia | Sample size: 72/0 Primary endpoint: percent area stenosis FU duration: 26 months |
| FATS, 1990 | niacin (1 g four times a day) and colestipol (10 g three times a day) (n=48) vs. placebo (or colestipol if the low-density lipoprotein [LDL] cholesterol level was elevated) (n=54) | men no more than 62 years of age with apolipoprotein B levels greater than or equal to 125 mg per deciliter, documented coronary artery disease, and a family history of vascular disease | double-blind Parallel groups Sample size: 48/54 Primary endpoint: FU duration: 2.5 years |
